Orbia Advance Corporation. de Valuation
Is ORBIA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ORBIA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ORBIA * (MX$25.65) is trading below our estimate of fair value (MX$27.36)
Significantly Below Fair Value: ORBIA * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORBIA *?
Other financial metrics that can be useful for relative valuation.
What is ORBIA *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.71b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1x |
Enterprise Value/EBITDA | 6.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ORBIA *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.5x | ||
ALPEK A ALPEK. de | 0.2x | 2.7% | Mex$25.8b |
CYDSASA A Cydsa. de | 0.7x | 9.6% | Mex$9.2b |
GCC * GCC. de | 2x | 4.6% | Mex$51.3b |
CMOCTEZ * Corporación Moctezuma. de | 3.3x | 5.6% | Mex$64.2b |
ORBIA * Orbia Advance Corporation. de | 0.3x | 5.2% | Mex$49.1b |
Price-To-Sales vs Peers: ORBIA * is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does ORBIA *'s PE Ratio compare vs other companies in the South American Chemicals Industry?
Price-To-Sales vs Industry: ORBIA * is good value based on its Price-To-Sales Ratio (0.3x) compared to the Global Chemicals industry average (1.3x).
Price to Sales Ratio vs Fair Ratio
What is ORBIA *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.3x |
Fair PS Ratio | 1x |
Price-To-Sales vs Fair Ratio: ORBIA * is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$25.65 | Mex$50.04 +95.1% | 32.1% | Mex$84.35 | Mex$34.36 | n/a | 13 |
Jul ’25 | Mex$25.49 | Mex$51.68 +102.7% | 30.6% | Mex$85.35 | Mex$34.76 | n/a | 13 |
Jun ’25 | Mex$27.66 | Mex$51.09 +84.7% | 26.2% | Mex$79.14 | Mex$35.63 | n/a | 12 |
May ’25 | Mex$28.14 | Mex$53.02 +88.4% | 24.7% | Mex$79.39 | Mex$36.95 | n/a | 13 |
Apr ’25 | Mex$35.10 | Mex$54.10 +54.1% | 22.6% | Mex$77.55 | Mex$37.40 | n/a | 14 |
Mar ’25 | Mex$31.83 | Mex$55.76 +75.2% | 22.0% | Mex$79.74 | Mex$41.57 | n/a | 14 |
Feb ’25 | Mex$34.26 | Mex$55.70 +62.6% | 20.8% | Mex$83.26 | Mex$41.32 | n/a | 14 |
Jan ’25 | Mex$37.62 | Mex$56.00 +48.8% | 20.8% | Mex$83.87 | Mex$41.62 | n/a | 14 |
Dec ’24 | Mex$38.04 | Mex$56.50 +48.5% | 21.0% | Mex$84.83 | Mex$42.10 | n/a | 14 |
Nov ’24 | Mex$30.95 | Mex$59.05 +90.8% | 20.6% | Mex$89.01 | Mex$44.17 | n/a | 14 |
Oct ’24 | Mex$36.21 | Mex$62.30 +72.0% | 22.2% | Mex$94.22 | Mex$42.95 | n/a | 13 |
Sep ’24 | Mex$39.14 | Mex$60.86 +55.5% | 22.1% | Mex$91.85 | Mex$41.87 | n/a | 13 |
Aug ’24 | Mex$37.49 | Mex$58.89 +57.1% | 22.3% | Mex$89.65 | Mex$43.20 | n/a | 13 |
Jul ’24 | Mex$36.88 | Mex$58.92 +59.8% | 22.3% | Mex$88.87 | Mex$44.36 | Mex$25.49 | 13 |
Jun ’24 | Mex$37.03 | Mex$59.60 +60.9% | 23.1% | Mex$88.83 | Mex$39.96 | Mex$27.66 | 13 |
May ’24 | Mex$41.42 | Mex$59.32 +43.2% | 22.6% | Mex$89.27 | Mex$40.16 | Mex$28.14 | 14 |
Apr ’24 | Mex$39.18 | Mex$58.57 +49.5% | 21.5% | Mex$88.98 | Mex$40.83 | Mex$35.10 | 14 |
Mar ’24 | Mex$38.06 | Mex$59.55 +56.5% | 21.9% | Mex$89.71 | Mex$41.16 | Mex$31.83 | 14 |
Feb ’24 | Mex$38.63 | Mex$58.24 +50.8% | 20.8% | Mex$86.05 | Mex$38.24 | Mex$34.26 | 14 |
Jan ’24 | Mex$34.50 | Mex$59.09 +71.3% | 21.5% | Mex$89.04 | Mex$39.57 | Mex$37.62 | 14 |
Dec ’23 | Mex$38.25 | Mex$58.45 +52.8% | 16.6% | Mex$74.27 | Mex$40.22 | Mex$38.04 | 15 |
Nov ’23 | Mex$34.33 | Mex$58.75 +71.1% | 17.1% | Mex$75.31 | Mex$40.78 | Mex$30.95 | 14 |
Oct ’23 | Mex$33.78 | Mex$60.55 +79.2% | 15.8% | Mex$74.80 | Mex$40.61 | Mex$36.21 | 14 |
Sep ’23 | Mex$38.51 | Mex$60.20 +56.3% | 16.0% | Mex$73.99 | Mex$40.94 | Mex$39.14 | 14 |
Aug ’23 | Mex$44.13 | Mex$63.98 +45.0% | 12.2% | Mex$75.73 | Mex$49.65 | Mex$37.49 | 14 |
Jul ’23 | Mex$46.94 | Mex$65.59 +39.7% | 9.8% | Mex$74.50 | Mex$52.23 | Mex$36.88 | 15 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.